SK바이오사이언스

302440KOSPI기초 의약물질 제조업

44.8 / 100

Reference Date: 2026-04-13

Financial Score14.5 / 40

News Sentiment14.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 3.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

SK Bioscience, established in 2018 as a spin-off from SK Chemicals, focuses on vaccine development and global CDMO services. Key products include cell-culture influenza vaccines like 'SkyCellflu' and the COVID-19 vaccine 'SkyCovion,' which received WHO PQ certification and global approvals. The company also provides CDMO services, collaborating with global pharmaceutical firms to produce and develop vaccines.

Number of Employees

1,129people

Average Salary

67.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 33.454.0Point

PBR

1.62Industry Average 2.034.0Point

In line with industry avg

ROE

-2.77Industry Average -4.293.5Point

Below industry avg

Debt Ratio

29.06Industry Average 6.610.0Point

4.4x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲57.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼522.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.4% (declining, 3yr)

Detailed News Sentiment

30 totalPositive 7Neutral 17Negative 1Average Sentiment Score 58.6

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 42,000Won52-week high 60,10052-week low 38,500

1-month return2.0Point

1m -3.89% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-03-27
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-26
Neutral최대주주등소유주식변동신고서2026-03-25
Neutral주식매수선택권부여에관한신고2026-03-23
Neutral정기주주총회결과2026-03-23